QualityStocks would like to highlight CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: aldoxorubicin (formerly known as INNO-206), tamibarotene, and bafetinib.
In the company’s news yesterday,
CytRx announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and evaluate the preliminary efficacy of its aldoxorubicin drug (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors that have failed to be helped by other therapies. Aldoxorubicin is a tumor-targeting conjugate of doxorubicin. Recent animal trials using this drug combination have showed favorable results in ovarian and pancreatic cancers.
The single-center Phase 1b clinical trial will be conducted under the direction of Dr. Sant P. Chawla, director of the Sancoma Oncology Center in Santa Monica, California, and will enroll up to 24 patients. Doxorubicin will be administered at 50% of its maximum tolerated dose in combination with escalating doses of aldoxorubicin to determine the maximum tolerated dose of this drug combination in this patient population.
In June, CytRx reported results for a Phase 1b/2 clinical trial indicating that aldoxorubicin administered at its maximum tolerated dose showed clinical benefit in 10 of 13 patients with relapsed or refractory soft tissue sarcoma (cancer). Based on these positive results, CytRx plans to meet with the FDA in the second half of 2012 to discuss a potential Phase 3 trial as a therapy for patients afflicted with soft tissue sarcoma whose tumors have progressed, even following chemotherapy treatment.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.